An Italian cannabis referendum could potentially lead to the decriminalisation of psychotropic substance cultivation, such as cannabis and mushrooms, for personal use if successful.
The successful completion of Phase I of the world’s first clinical trial investigating the use of DMT-assisted therapy could lay the foundation for a “new paradigm”...
Psychiatrist Dr Tiago Reis Marques discusses what new research findings on ketamine mean for treatment-resistant mental conditions such as major depressive disorder.
Mind Cure Health has joined the Digital Therapeutics Alliance in a bid to drive awareness and adoption of digital therapies.
As the ecosystem around psychedelics in Europe develops, UK-based Clerkenwell Health is cementing itself as a serious player on the continent with the appointment of clinical...
The Multidisciplinary Association for Psychedelic Studies (MAPS) has received funding of $1.5m from Wasana Health in a first-of-its-kind collaboration to accelerate research into MDMA-assisted therapy for...
A new, pooled analysis has found that single-dose, clinical administration of LSD is safe in regards to acute psychological and physical harm in healthy subjects.
The first patient has received a dose of psilocybin in the world’s first trial investigating psilocybin as a treatment for a rare and debilitating headache disorder...
Atai Life Sciences and Introspect Digital Therapeutics will be testing a novel, digital therapeutic approach for patients using ketamine for treatment resistant depression.
Origin Therapeutics is poising for public listing on the Canadian Securities Exchange (CSE).